"With the successful completion of this proof-of-concept study in HCV-infected patients, Biotron plans to advance BIT225 into a 14 day dose ranging study in combination with the current standard of care, interferon-alpha and ribavirin."
The news is a very good milestone for BIT. It is working on its own in people to reduce the viral load!
I wonder when the above mentioned trial (from today's announcement) will start. Interesting to see if it will attract a partner for funding it from this success and also to fund the HIV trials for which BIT225 was originally designed for.
great result from biotron, page-4
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
